Héritier Obed Lango

Factors Associated with Virological Failure under Dolutegravir-based Therapy in HIV-1 Infected Patients in the Central African Republic (2023–2025)

Laris Michael Dan-Houron Bejendo, Héritier Obed Lango, Clotaire Donatien Rafaï, Christelle Luce Bobossi, Serge Gbazi, Wanh-Ingo Hissein Hereidebona, Bokia Coretha Baguida, Moynam Heredeibona, Boniface Koffi & Ernest Lango-Yaya · Microbiology Research Journal International · 2026

Introduction: HIV‑1 remains a major public health issue, with a prevalence of 3.5% in the Central African Republic. Dolutegravir (DTG)-based regimens are recommended as first-line therapy due to their high efficacy and resistance barrier, yet virological failure persists, influen...

Open access Research Article 10.9734/mrji/2026/v36i51746

Sentinel surveillance of the WHO-Validated Pfkelch13 C580Y Artemisinin Resistance Marker in Plasmodium falciparum Isolates from Bangui, Central African Republic

Moynam Ekte Heredeibona, Aroun Abdel Nassir, Bejendo Dan-Houron, Héritier Obed Lango, Christelle Luce Bobossi, Coretha Bokia Baguida, Ernest Lango-Yaya, Boniface Koffi, Emile Minyaka & Romaric NzoumbouBoko · Microbiology Research Journal International · 2026

Background: Artemisinin-based combination therapies (ACTs) are the cornerstone of malaria treatment. However, partial artemisinin resistance associated with mutations in the Plasmodium falciparum Pfkelch13 propeller domain threatens malaria control efforts. The C580Y substitution...

Open access Research Article 10.9734/mrji/2026/v36i61751